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Letter to the Editor
Extraordinarily Fast Response to Low-Dose Sertraline
in a Child with Severe Obsessive-Compulsive Disorder
and High Functioning Serotonin Transporter Genotype
Edna Gru¨nblatt, PhD, Senop Tschakarjan, MD, Veronika Brezinka, PhD, and Susanne Walitza, MD
To The Editor:
Obsessive-compulsive disorder (OCD) is a heterogeneouspsychiatric disorder characterized by clinically significant,
recurrent, intrusive, and disturbing thoughts (obsessions), accom-
panied by repetitive, stereotypic behaviors that are usually asso-
ciated with anxiety or dread (compulsions) (American Psychiatric
Association 2000). The familiality is especially high for early-onset
OCD, with earlier age of onset corresponding to a higher proba-
bility of first-degree relatives also being affected by OCD (Walitza
et al. 2010). Selective serotonin reuptake inhibitors (SSRIs) are
the first choice drugs for children and adolescents with OCD, as
they are both highly effective and well tolerated. A meta-analysis
showed that cognitive behavioral therapy (CBT) is also highly ef-
fective, with a mean effect strength of 1.55 (Freeman et al. 2007).
Moreover, the Pediatric OCD Treatment (POTS) study of the ef-
fects of CBT, SSRI medications, and combination therapy com-
pared with placebo demonstrated that medication management plus
CBT was superior to either strategy alone on all outcome measures
(Franklin et al. 2003, 2011).
It is well known that higher SSRI dosages are needed to obtain
positive treatment responses in OCD compared with dosages nee-
ded in depression. Furthermore, SSRIs are metabolized more rap-
idly in young patients than in adults, which can also cause the
dosage requirements to be relatively higher, that is, up to 80mg
daily of fluoxetine (Bezchlibnyk-Butler and Virani 2007). When
SSRIs are given, the beneficial effects are typically expected to
begin only after 4–10 weeks of treatment, and, therefore, the effect
should only be judged after 8–12 weeks of treatment have elapsed
(Wagner et al. 2003; Findling et al. 2006).
As SSRIs are the most effective medications for OCD treatment,
many molecular genetic association studies in OCD have focused
on serotonergic genes. The most frequently studied gene is the
serotonin transporter (SERT; SCL6A4), with particular focus on its
functional polymorphism, 5-HTTLPR, in the upstream region.
Comparison between the S-[short] and L-[long] alleles of 5-
HTTLPR shows that the L-allele exerts increased transcriptional
activity and increased basal reuptake of serotonin in vitro (Heils
et al. 1996; Lesch et al. 1996; Murphy et al. 2008). The L-allele is,
therefore, referred to as the gain-of-function variant of the seroto-
nin transporter.
Recent findings have led to the subdivision of the 5-HTTLPR
L-allele into the high-functioning LA-alleles and low-functioning
LG-alleles. When this new classification is used, *5–10% of
L-alleles (depending on ethnicity) are deemed low functioning and
must be grouped with the S-alleles for comparison purposes (Hu
et al. 2006). Additional single-nucleotide polymorphisms (SNPs)
on the serotonin transporter (SERT) have also recently been re-
ported to influence functionality of the transporter, that is,
rs16965628 with C-allele >G-allele (high> low) and rs25532 with
C-allele >T-allele (Wendland et al. 2008).
Case Report
The present report describes the case of a 7-year-old boy
(henceforth referred to as P.) with rather severe early-onset OCD,
who exhibited an extraordinarily fast positive response to sertraline
in a low dose of 25mg. The boy was first registered at our clinic in
May 2009, and the referral letter indicated that, 3 months prior, the
boy had started to refuse to eat anything ‘‘hard.’’ The symptom
increased with such severity that at the time of referral the boy was
not swallowing his own sputum, because of fear of choking. In
addition, he had developed cleaning compulsions. Somatic exam-
inations were inconspicuous. A 4 week CBT did not reduce the
symptomatology substantially; therefore, 25mg sertraline was in-
troduced. After only 2 days, significant symptom reduction was
observed. After 2 weeks, most of the previously described OCD
symptoms had disappeared. For several reasons CBT was im-
plemented again: 1). Because of the guidelines of OCD therapy in
which a combination of medication with CBT is the first line
therapy for children with OCD (Walitza et al. 2011) and 2) in some
cases, CBT is only possible or successful if medication precedes the
psychological therapy. Therefore, although there was such a good
effect, we implemented CBT again after some weeks of good re-
sponse to medication (for timeline, see Supplementary Fig. 1) (see
online supplementary material at http://www.liebertonline.com/
jcap). In February 2011, as the parents felt that the patient’s mental
health status had acceptably stabilized, they tried to discontinue the
medication. Approximately 1 week after discontinuation, P.’s
symptomatology began to deteriorate. Therefore, after 1 month it
was decided to re-launch the medication with 25mg sertraline, after
which P.’s symptoms stabilized very quickly. Medication was
discontinued two more times because of the parents’ strong wish to
see whether symptomatology remained in remission without
medication (summers of 2011 and 2012); both times, the symp-
tomatology increased after *1 week, with intolerable and severe
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OCD and accompanying symptoms. Withdrawal effects, increased
anxious symptoms, and restlessness appeared during and directly
after each discontinuation. Therefore, 25mg sertraline was re-
sumed after 1–2 weeks of discontinuation, with an immediate im-
provement (for detailed case description see Supplementary Text 1)
(see online supplementary material at http://www.liebertonline
.com/jcap). Based on this observation, we further tested whether
this case involved gene modifications in the serotonergic system
and/or in the enzyme cytochrome P-450 (CYP), which is known to
metabolize sertraline (Kobayashi et al. 1999; Ingelman-Sundberg
2001, 2004; Obach et al. 2005) (for detailed method description see
Supplementary Text 2) (see online supplementarymaterial at http://
www.liebertonline.com/jcap).
Genotyping results
Genotyping 5-HTTLPR and the SNPs rs25531, rs16965628,
and rs25532 showed that the child was homozygous for the LA-
allele of 5-HTTLPR (high-functioning transporter), as well as
for rs16965628 with GG (lower-functioning transporter) and for
rs25532 with CC (high-functioning transporter) (Fig. 1). Thorough
genotyping of all known CYP isoform polymorphisms affecting
sertraline metabolism revealed that the boy was homozygous
wild-type (normal metabolizing) for CYP2C9*2 (CC), CYP2C9*3
(AA), CYP2C19*3 (GG), CYP2D6*4 (GG), and CYP3A4*2 (TT).
For CYP2C19*2, he was homozygous for the mutation AA, which
is known to cause defective splicing and an inactive enzyme (In-
gelman-Sundberg 2001, 2004) (Fig. 1). Analysis of the two copy
number variations (CNVs) on CYP2D6*5 showed that both re-
sulted in two normal copies, and not in a deletion of the gene that
causes no enzyme expression.
Discussion
In this case, we found that a 7-year-old child with early-onset
OCD was a carrier of two high-functioning SERT polymorphisms
(5-HTTLPR, LALA; rs25532, CC) and one SNP for the low-
functioning SERT (rs16965628, GG) (Fig. 1). These results may
relate to the patient’s very rapid response to a rather low dose of
sertraline. Our findings are in accordance with previous observa-
tions of SERT genotype effects on SSRI therapy response in de-
pression (Porcelli et al. 2012), and on sertraline therapy response in
posttraumatic stress disorder (PTSD) (Mushtaq et al. 2011). The
discontinuation syndrome experienced on each occasion after ser-
traline withdrawal—in which P became restless and anxious and
had sleeping disturbances—is also in accordance with previous
reports in the literature (Hosenbocus and Chahal 2011).
To rule out possible low drug metabolism through CYP en-
zymes, we analyzed all major isoforms known to metabolize ser-
traline, and found that only one isoform was mutated to cause an
inactive isoform (and consequently low metabolism), whereas all
six gene variants were homozygous for the active enzyme (Fig. 1).
Sertraline metabolism occurs through the activity of multiple
CYP isoforms rather than by only one isoform; therefore, it has been
suggested that no single agent (inhibitor) or single drug-metabolizing
enzyme genetic polymorphism could impact the pharmacokinetics
of sertraline (Kobayashi et al. 1999; Obach et al. 2005).
One very small study of six poor metabolizers and six extensive
metabolizers reported that the polymorphic CYP2C19 might be a
major enzyme involved in sertraline N-demethylation (Wang et al.
2001). However, the studies of de Morais et al. (1994) and Obach
et al. (2005) show that sertraline metabolism is highly complex, and
involves many CYP isoforms, indicating that a series of mutations
would be required to definitely cause poor sertraline metabolism.
Moreover, a recent study of the therapy response and side effects
following treatment of a large OCD cohort with antidepressants
investigated associations with the metabolizer status of CYP2D6
and CYP2C19, and found a nonsignificant trend for association of
CYP2C19 metabolizer status with response to sertraline (Brandl
et al. 2013). In the case reported here, only one isoform was mu-
tated, and all other isoforms were normal, indicating that sertraline
metabolism was likely normal in this child, and that the main effect
probably came from the SERT genotype. This is also supported by
the normal levels of plasma sertraline that were detected in this
patient after 2 weeks of therapy.
Limitations
The genotype is certainly not the only etiological factor that
could be responsible for the patient’s OCD symptomatology. It
must be considered that children and adolescents often show a flat
dose-response curve, meaning that initial dosages can lead to a
positive response (Walitza et al. 2011). However, previous findings
in early-onset OCD support the idea that the gain-of-function al-
leles of 5-HTTLPR are risk factors for OCD (Personal data not yet
published). It should also be noted that it is impossible to com-
pletely rule out the possibility of a placebo effect in this case report.
However, as it was repeatedly observed during a period of > 3 years
that when P. discontinued his medication, his symptoms returned,
we can assume that the beneficial effects were at least partly the
result of the sertraline therapy.
FIG. 1. Genotype profile of a 7-year-old boy with early-onset
obsessive-compulsive disorder (OCD) for the serotonin trans-
porter (SERT) gene and the cytochrome P450 (CYP) isoforms that
are known to metabolize sertraline. Left side, high-functioning
SERT or active CYP isoform; Right side, low-functioning SERT
or inactive CYP isoform.
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Clinical Significance
The results of this case could assist with making the decision
whether or not to continue treatment of a child for a longer time if
side effects are not observed. The observed repeated discontinuation
syndrome indicates that in a highly sensitive patient, such as this
case, cessation of sertraline medication should be done with caution.
Pharmacogenetic studies of single cases could be helpful in under-
standing therapeutic effects and, in the best case, could improve
efficacy and safety of medication in children and adolescents.
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